On World Sleep Day Idorsia highlights the publication of a global study on the economic and societal impact of chronic insomnia disorder - Seite 2

As part of the company’s ongoing commitment to advance research in insomnia, Idorsia supports RAND Europe’s recommendation and highlights the importance of:

• Incorporating insomnia screening during routine clinical visits
• Addressing physician knowledge gaps and improving the identification and management of insomnia
• Conducting more research on the prevalence of CID and its societal and economic impacts
  
  

Jean-Paul Clozel, MD and Chief Executive Officer of Idorsia, commented:
“Our scientists have over 20 years of experience in the field of sleep research, through the orexin system, and continue to work on better understanding of the science of sleep and chronic insomnia disorder. An example of our commitment to furthering this understanding is our sponsorship of the research published by RAND Europe. Their findings are unique by revealing, for the first time, the indirect economic and ‘hidden’ wellbeing costs of chronic insomnia disorder. Despite sleep being a biological necessity to ensure optimal functioning throughout the day,⁵ millions of people globally are not getting restorative sleep due to chronic insomnia disorder. It's important that we acknowledge chronic insomnia as a legitimate medical condition and recognize the enormous burden it places on individuals and society as a whole.”

According to the recently published figures, the cost of chronic insomnia disorder is substantial. In terms of indirect costs, chronic insomnia disorder was associated with approximately 11 to 18 days of absenteeism, 39 to 45 days of presenteeism (defined as reduced productivity while at work), and 44 to 54 days of overall productivity loss annually. This equates to an estimated loss in annual GDP of approximately $170.7 billion for the 12 European countries analyzed, $19.6 billion for Canada and $207.5 billion for the United States.^* The indirect economic costs reported by RAND are higher than costs reported in other literature.¹

It was found that people suffering from insomnia, including chronic insomnia disorder, would be willing to trade, on average, an estimated 14.0% of their per capita household income in order to recuperate the wellbeing loss associated with the condition.^* From this, population level intangible costs were estimated to be $92 billion across 12 countries in Europe, $10.7 billion in Canada and $127.1 billion per year in the United States for those of working-age range.¹